AbbVie reached a voluntary agreement with the U.S. administration committing up to $100 billion in U.S. research, development and manufacturing investments over the next decade tied to expanded patient access programs, including an extension of the TrumpRx direct‑to‑patient initiative. The pact includes confidential commercial terms and regulatory concessions such as tariff exemptions, and AbbVie said it will expand access programs for key medicines. The deal aims to bolster domestic manufacturing and patient affordability while aligning company investment plans with federal priorities. Observers noted the agreement raises policy and competition questions—particularly around pricing concessions, export impacts and how the government balances incentives against long‑term drug pricing reforms.